Late CMV Disease and/or Recurrence in Renal Transplants Recipients with Prolonged Oral Ganciclovir Prophylaxis

Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

Volumn 15, Issue 2, 2003, Pages 105-109

  Gómez, Ernesto ^a   Laures A S ^a   Melon S ^a   Baltar, J M ^a   De Ona M ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Antigenemia; CMV disease; Oral GCV prophylaxis; PCR

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION;

EID: 17144448309     PISSN: 09469648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rubin RH (1993) Infectious disease complications of renal transplantation. Kidney Int 44: 221
2. Brennan DC (2001) Cytomegalovirus in Renal Transplantation. J Am Soc Nephrol 12: 848
3. Crumpacker CS (1996) Ganciclovir. N Engl J Med 335: 721
4. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C (1998) Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation. Transplantation 65: 641
5. Gane E, Saliba F, Valdecasas GJ et al. (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350: 1729
6. Turgeon N, Fishman JA, Basgoz N et al. (1998) Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 66: 1780
7. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T et al. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70: 1174
8. Boehler A, Schaffner A, Salomon F, Keusch G (1994) Cytomegalovirus disease of late onset following renal transplantation: a potentially fatal entity. Scand J Infect Dis 26: 369
9. Tenney F, Sakarcan A (2001) Fatal cytomegalovirus disease in a high-risk renal transplant recipient. Pediatr Nephrol 16: 8
10. Razonable RR, Rivero A, Rodriguez A et al. (2001) Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant receiving prophylaxis with oral ganciclovir. J Infect Dis 184: 1461
11. Boeckh M, Leisenring W, Riddell SR et al. (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407
12. Limaye AP, Corey L, Koelle DM et al. (2000) Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356: 645
13. Turgeon N, Fishman JA, Doran M et al. (2000) Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transplant Infect Dis 2: 2-10
14. Mendez JC, Sia IG, Tau KR et al. (1999) Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 67: 755
15. Markham A, Faulds D (1994) Ganciclovir: An update of its therapeutic use in Cytomegalovirus infection. Drugs 48: 455
16. Gómez E, Aguado S, Melón S, Martínez A, de Oña M, Cimadevilla R, Gorostidi M, González E, Alvarez-Grande J (1992) A prospective study of the usefulness of rapid diagnostic tests in monitoring CMV infection in renal transplant. Transplant Proc 21: 2631-2633
17. Read SJ, Jeffery K, Bangham C (1997) Aseptic meningitis and encephalitis: the role of PCR in the diagnostic laboratory. J Clin Microbiol 35: 691-696
18. Hibberd PL, Tolkoff-Rubin NE, Conti D et al. (1995) Preemptive ganciclovir therapy to prevent CMV disease in CMV antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 123: 18
19. Smith S, Butterly DW, Alexander BD, Greenberg A (2001) Viral Infection after transplantation. Am J Kid Dis 37 (4): 659-676
20. Gomez E, de Oña M, Melón S, Alvarez R, Laures A, Rodriguez M, Pobes A, Alvarez-Grande J (1999) Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression. Nephron 82 (3): 238-245
21. Becker BN, Becker YT, Leverson GE et al. (2002) Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kid Dis 39: 1088
22. Limaye AP, Corey L, Koelle DM, Davis CL, Boeck M (2000) Emergence of ganciclovir-resistant CMV disease among solid-organ transplants. Lancet 536: 645-649
23. Baldanti F, Limoncini L, Sarasin A, Zavattoni M, Grossi P, Revello MG, Gerna G (1998) Ganciclovir resistance as a result of oral GCV in a heart transplant recipient with multiple CMV strains in the blood. Transplantation 66: 324-329
24. de Oña M, Melón S, Mendéz S, Iglesias B, palacios A, Bernardo MJ., Rodríguez-Lambert JL, Gómez E (2002) Assay of Citomegalovirus susceptibility to ganciclovir in renal and heart transplant recipients. Transplant International 11: 570-573
25. Gilbert C, Roy J, Belanger R, Delage R, Beliveau C, Demers C, Boivin G (2001) Lack of emergence of CMV UL97 mutations conferring GCV resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 45 (12): 3669-71
26. Rubin R, Tolkoff-Rubin N (1993) Antimicrobial strategies in the care of organ transplant recipients. Antimicrobiol Agents Chemother 37: 619-624
27. Mendez JC, Espy MJ, Smith TF, Wilson JA, Paya CV (1998) Evaluation of PCR primers for early diagnosis of CMV infection following liver transplantation. J Clin Microbiol 36: 526-530
28. Singh N (2001) Preemptive therapy or universal prophylaxis with ganciclovir for CMV in solid organ transplant recipients. Clin Infect Dis 32 (5): 742-51
29. Lowance D, Neumayer HH, Legendre CM et al. (1999) Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340: 1462
30. Akalin E, Sehgal V, Ames S et al. (2003) Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Med 3: 731-5